NPM1 and acute myeloid leukemia: From the total of 199 CN-AML patients in this study, FLT3-ITD, FLT3-D835 and NPM1 mutations were detected in 16.1% (32/199), 2.5% (5/199), and 27.1% (54/199) respectively.